In the past week, EVOK stock has gone up by 172.00%, with a monthly gain of 145.26% and a quarterly surge of 207.88%. The volatility ratio for the week is 5.49%, and the volatility levels for the last 30 days are 8.83% for Evoke Pharma Inc The simple moving average for the last 20 days is 143.33% for EVOK stock, with a simple moving average of 78.38% for the last 200 days.
Is It Worth Investing in Evoke Pharma Inc (NASDAQ: EVOK) Right Now?
Moreover, the 36-month beta value for EVOK is -0.08. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EVOK is 1.41M and currently, short sellers hold a 1.26% of that float. On July 09, 2025, EVOK’s average trading volume was 15.70K shares.
EVOK) stock’s latest price update
Evoke Pharma Inc (NASDAQ: EVOK) has seen a rise in its stock price by 172.00% in relation to its previous close of $2.66. However, the company has experienced a 172.00% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-09 that SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis.
Analysts’ Opinion of EVOK
Many brokerage firms have already submitted their reports for EVOK stocks, with H.C. Wainwright repeating the rating for EVOK by listing it as a “Buy.” The predicted price for EVOK in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 22, 2020 of the previous year 2020.
B. Riley FBR Inc. gave a rating of “Buy” to EVOK, setting the target price at $5 in the report published on March 08th of the previous year.
EVOK Trading at 130.06% from the 50-Day Moving Average
After a stumble in the market that brought EVOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.27% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVOK starting from Nantahala Capital Management, who sale 41 shares at the price of $4.39 back on Jan 28 ’25. After this action, Nantahala Capital Management, now owns 148,153 shares of Evoke Pharma Inc, valued at $180 using the latest closing price.
Stock Fundamentals for EVOK
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.97 for the gross margin
The net margin for Evoke Pharma Inc stands at -0.44. The total capital return value is set at -0.84. Equity return is now at value -108.77, with -35.23 for asset returns.
Based on Evoke Pharma Inc (EVOK), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -26.77. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -10.01.
Currently, EBITDA for the company is -4.85 million with net debt to EBITDA at 2.73. When we switch over and look at the enterprise to sales, we see a ratio of -0.19. The receivables turnover for the company is 4.62for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
To wrap up, the performance of Evoke Pharma Inc (EVOK) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
